Attention Deficit Hyperactivity Disorder - Pipeline Insight, 2024

This “Attention Deficit Hyperactivity Disorder- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Attention Deficit Hyperactivity Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Attention Deficit Hyperactivity Disorder: Understanding

Attention Deficit Hyperactivity Disorder: Overview

Attention Deficit-Hyperactivity Disorder (ADHD) is a psychiatric condition that has long been recognized as affecting children's ability to function. Individuals suffering from this disorder show patterns of developmentally inappropriate levels of inattentiveness, hyperactivity, or impulsivity. Although there used to be two different diagnoses of Attention Deficit Disorder vs. Attention Deficit Hyperactivity Disorder, the DSM IV combined this into one disorder with three subtypes: predominantly inattentive, predominantly hyperactive, or combined type.

The symptoms begin at a young age and usually include lack of attention, lack of concentration, disorganization, difficulty completing tasks, being forgetful, and losing things. These symptoms should be present before the age of 12, have lasted six months, and interfere with daily life activities in order to be labeled as 'ADHD.' This must be present in more than one setting (i.e., at home and school, or school and after-school activities). It can have large consequences, including social interactions, increased risky behaviors, loss of jobs, and difficulty achieving in school.

ADHD must be considered within the context of what is developmentally and culturally appropriate for a person. It is considered a dysfunction of executive functioning, predominantly a frontal lobe activity. Therefore, patients with ADHD show disability not only in attention and focus but also in decision making and emotional regulation. Children with ADHD can have difficulty with social interactions, can be easily frustrated, and can be impulsive. They are often labeled as trouble makers.

ADHD is associated with cognitive and functional deficits that relate to diffuse abnormalities in the brain. The anterior cingulate gyrus and dorsolateral prefrontal cortex (DLFPC) are found to be small in individuals who are suffering from ADHD. It is thought that these changes account for the deficits in goal-directed behavior. Moreover, activity in the frontostriatal region is also reduced in these individuals as measured by fMRI. It is important to understand these pathophysiological mechanisms so that the pharmacotherapy is directed onto them. It is important to remember that ADHD is a clinical diagnosis. There are no standard laboratory or imaging results among patients with ADHD.

The etiology of ADHD is related to a variety of factors that include both a genetic and an environmental component. It is one of the most heritable conditions in terms of psychiatric disorders. There is a much greater concordance in monozygotic twins than dizygotic. Siblings have twice the risk of having ADHD than the general population. Similarly, viral infections, smoking during pregnancy, nutritional deficiency, and alcohol exposure in the fetus have also been explored as possible causes of the disorder. There are no consistent findings on brain imaging of patients with ADHD. The number of dopaminergic receptors has also been implicated in the development of the disorder whereby research has shown that the receptors are decreased in the frontal lobes in individuals with ADHD. There is also evidence for the role of noradrenergic receptor involvement in ADHD.

Attention Deficit Hyperactivity Disorder- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Attention Deficit Hyperactivity Disorder pipeline landscape is provided which includes the disease overview and Attention Deficit Hyperactivity Disorder treatment guidelines. The assessment part of the report embraces, in depth Attention Deficit Hyperactivity Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Attention Deficit Hyperactivity Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Attention Deficit Hyperactivity Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Attention Deficit Hyperactivity Disorder.

Attention Deficit Hyperactivity Disorder Emerging Drugs Chapters

This segment of the Attention Deficit Hyperactivity Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Attention Deficit Hyperactivity Disorder Emerging Drugs

CTx-1301: Cingulate TherapeuticsCTx-1301 utilizes Cingulate’s innovative Precision Timed Release (PTR) drug delivery platform technology to create a breakthrough multi-core formulation of dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. CTx-1301 combines layers of immediate release and sustained release active pharmaceutical ingredient (API) in a single tablet intended to deliver the right amount of drug at the right time when patients need it; delivering a rapid onset and entire active day efficacy while providing a controlled descent of plasma drug levels to optimize treatment. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Attention-deficit hyperactivity disorder.

Centanafadine: Otsuka PharmaceuticalCentanafadine is a serotonin-norepinephrine-dopamine, triple-reuptake inhibitor. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. Approximately, 900 adult patients from age 18 to 55 years old, and diagnosed with ADHD, were randomized in the two phase III studies. The studies were randomized, double-blind, multicenter, and placebo-controlled with parallel groups. Patients were randomized 1:1:1 to receive either centanafadine doses of 100 or 200 mg, twice daily (total daily dose of 200 mg or 400 mg, respectively), or placebo twice daily. Centanafadine demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both investigational studies. In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients.

PDC-1421: BioLite, Inc.PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd) as active ingredient. American BriVision receives approval of Taiwan Central Institutional Review Board (CIRB) to initiate a Phase II part 2 study in Attention-deficit hyperactivity disorder (ADHD) in Taiwan. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Attention-deficit hyperactivity disorder.

Attention Deficit Hyperactivity Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Attention Deficit Hyperactivity Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Attention Deficit Hyperactivity Disorder

• There are approx. 20+ key companies which are developing the therapies for Attention Deficit Hyperactivity Disorder. The companies which have their Attention Deficit Hyperactivity Disorder drug candidates in the most advanced stage, i.e. phase III include, Cingulate Therapeutics.

Phases

This report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Attention Deficit Hyperactivity Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Attention Deficit Hyperactivity Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Attention Deficit Hyperactivity Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Attention Deficit Hyperactivity Disorder drugs.

Attention Deficit Hyperactivity Disorder Report Insights

• Attention Deficit Hyperactivity Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Attention Deficit Hyperactivity Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Attention Deficit Hyperactivity Disorder drugs?
• How many Attention Deficit Hyperactivity Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Attention Deficit Hyperactivity Disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Attention Deficit Hyperactivity Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Attention Deficit Hyperactivity Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cingulate Therapeutics
• Otsuka Pharmaceutical
• BioLite
• Mind Medicine
• Tris Pharma
• RespireRx Pharmaceuticals
• KemPharm
• Arbor Pharmaceuticals
• Ensysce Biosciences
• 3Z Pharmaceuticals

Key Products

• CTx-1301
• Centanafadine
• PDC-1421
• MM-120
• TRN-148
• CX717
• KP922
• AR19
• PF8001
• 3Z-20-001

This product will be delivered within 1-3 business days.